Risks
4 risks
Risk Intelligence
US FDA delays on biosimilar approvals
View Risks →
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's Q2 FY26 revenue grew 9.8% YoY to INR 8,805 crore, driven by broad-based growth across markets and the acquired NRT business, partially offset by lower Revlimid sales and US price erosion. EBITDA margin contracted 174 bps YoY to 26.7% due to product mix and one-time provisions. PAT rose 14% YoY to INR 1,437 crore, aided by lower tax rate. Management reiterated confidence in returning to 25%+ EBITDA margins over two years, supported by cost initiatives and pipeline assets like semaglutide and abatacept. Key risks include US FDA delays on biosimilar approvals and competitive pricing in Canada for semaglutide.
डॉ. रेड्डी की दूसरी तिमाही में कमाई पिछले साल से 9.8% बढ़कर 8,805 करोड़ रुपये हो गई। यह बढ़ोतरी सभी बाजारों में अच्छी बिक्री और नए खरीदे गए NRT व्यवसाय से हुई, लेकिन Revlimid की कम बिक्री और अमेरिका में दवाओं के दाम गिरने से कुछ असर पड़ा। कंपनी का मुनाफा (PAT) 14% बढ़कर 1,437 करोड़ रुपये हो गया, क्योंकि टैक्स कम लगा। हालांकि, कंपनी की कमाई पर खर्च का अनुपात (EBITDA मार्जिन) 26.7% रहा, जो पिछले साल से 1.74% कम है। इसकी वजह उत्पादों का मिश्रण और एक बार का खर्च था। कंपनी का कहना है कि वह अगले दो साल में 25% से अधिक मार्जिन पर लौट आएगी, जिसके लिए लागत कम करने और नई दवाओं (जैसे semaglutide और abatacept) पर ध्यान दिया जा रहा है। जोखिमों में अमेरिकी FDA की देरी और कनाडा में semaglutide की कीमत प्रतिस्पर्धा शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue
$373M
-16% YoY
Decline driven by price erosion and lower Revlimid sales.
India Business Revenue
INR 1,578 Cr
+13% YoY
Double-digit growth driven by new launches and market share gains.
Semaglutide Pen Capacity
12M pens
N/A
Management confident of selling 12 million pens in first 12 months post-launch.
R&D Spend as % of Revenue
7%
-203 bps YoY
Decline due to reduced biosimilar development spend; expected to stay in this range.
What Changed vs Last Quarter
NEW
EBITDA margin to return to 25%+ in two years
Management maintains commitment to achieving 25%+ EBITDA margins within the next two years, driven by cost efficiencies and pipeline growth.
NEW
Abatacept BLA submission by end of December 2025
BLA for abatacept IV will be submitted by end of calendar 2025, with high confidence in approval.
NEW
Semaglutide launch in 87 countries within 12-15 months
Expects to obtain approval in 87 countries and launch 12 million pens, with Canada as a key market.
NEW
PSAI gross margin to improve to 20-25%
CFO guided PSAI gross margin to be in the 20-25% range going forward, up from 18% in Q2.
DROPPED
Semaglutide launch in Canada by early 2026
Expects approval between end-Oct and early-Nov 2025, with launch at LOE in Jan 2026, subject to IP clearance and approval.
DROPPED
R&D spend 7%-7.5% of sales for FY26
R&D investments expected in this range for the full fiscal year.
DROPPED
CapEx outflow INR 2,500-2,700 crore for FY26
Capital expenditure for the full year expected in this range, primarily for peptides and biosimilars.
DROPPED
EBITDA margin aspiration of 25%+ for base business
Aims to maintain EBITDA margin north of 25% for the base business, with semaglutide expected to be accretive.
NEW RISK
US FDA delays on biosimilar approvals
Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.
NEW RISK
Revlimid revenue decline
Revlimid sales are declining faster than expected, with Q3 likely the last quarter of meaningful contribution.
NEW RISK
Semaglutide Canada pricing and competition
Multiple filers and potential compounding pharmacy entry could lead to aggressive pricing and lower margins.
NEW RISK
Patent litigation outcome in India for semaglutide
Awaiting Delhi High Court decision; adverse ruling could delay India launch and impact export plans.
RISK GONE
Lenalidomide revenue decline sharper than expected
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
RISK GONE
Semaglutide launch delays due to IP or regulatory hurdles
Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.
RISK GONE
US generic price erosion persists
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
RISK GONE
SG&A costs may remain elevated
SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q1 FY26, Q2 FY25, Q3 FY25
R&D investments expected in this range for the full fiscal year.
Mentioned in Q1 FY26, Q3 FY25, Q4 FY25
Expects approval between end-Oct and early-Nov 2025, with launch at LOE in Jan 2026, subject to IP clearance and approval.
Mentioned in Q1 FY25, Q1 FY26
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
Fast read
Guidance and risk preview
Management maintains commitment to achieving 25%+ EBITDA margins within the next two years, driven by cost efficiencies and pipeline growth.
Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.
View Risks →